Potential obesity candidate dropped by Novo despite phase I success
Development of appetite regulating peptide LA-GDF15, which had just completed phase I testing, has been terminated.
by christopher due karlsson, translated by daniel pedersen
In September, Novo Nordisk concluded a successful phase I trial of LA-GDF15, an appetite regulating candidate for obesity treatment.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk on track to secure Wegovy doses
For subscribers
New Novo Nordisk treatment targets 25% weight loss
For subscribers
